Background and Purpose-The impact of smoking on prognosis after stroke is controversial. We aimed to assess the relationship between smoking status and stroke outcome after intravenous thrombolysis in a large cohort study by adjusting for potential confounders and incorporating recanalization rates. Methods-In a prospective observational multicenter study, we analyzed baseline and outcome data of consecutive patients with acute ischemic stroke treated with intravenous thrombolysis. Using uni-and multivariable modeling, we assessed whether smoking was associated with favorable outcome (modified Rankin Scale score of 0-1) and mortality. In addition, we also measured the occurrence of symptomatic intracranial hemorrhage and recanalization of middle cerebral artery.
C igarette smoking is a well-known independent and modifiable risk factor for stroke in both men and women. 1, 2 Recent data indicate that ≈20% of strokes are attributable to tobacco use, which may be even higher in younger patients with cryptogenic stroke. 3 Paradoxically, several studies suggested an association between smoking and good clinical outcome in patients treated with tPA (tissue-type plasminogen activator). This observation has been called smoking paradox in literature and was first described in patients with myocardial infarction. 4, 5 The effect of smoking on stroke outcome after intravenous thrombolysis (IVT) is controversial, but recent studies reported higher rates of recanalization, lower risk for cerebral hemorrhage, and better clinical outcomes in smokers. [6] [7] [8] We hypothesize that these observations may be rather caused by differences in clinical characteristics at baseline than by biological effects of smoking. We therefore conducted a large prospective study with indepth analysis of clinical and radiological data to explore the association between smoking and outcome of ischemic stroke after IVT.
Methods

Study Design and Setting
As a joint initiative of 4 Swiss stroke centers (Berne, Basel, Zurich, Lausanne), we performed an observational multicenter cohort study to determine the impact of smoking status on stroke outcome after IVT. Detailed data on the number of consecutive patients and study period for each center are available as Table I in the online-only Data Supplement. The study was approved by the ethics committee in Berne. The requirement for additional local ethical approval and written informed consent differed between participating centers and was obtained if required. The data that support the findings of this study are available from the corresponding author on reasonable request.
Participants
Patients needed to meet the following 3 criteria for study inclusion: (1) treatment with IVT (alteplase) for acute ischemic stroke according to the current guidelines of the European Stroke Organization, 9 (2) obtainable information about smoking status of the patient, and (3) availability of outcome data at 3 months. Patients were classified as smokers when they reported active cigarette use.
Data Sources and Handling
Data from individual patients were systematically and prospectively collected in each center by using a standardized form with predefined variables as applied in previous studies. 10 Compilation of completed forms from all centers and analyses of the pooled data were performed in the coordinating center in Berne, Switzerland. The study was approved by the ethics committee in Berne. The requirement for additional local ethical approval differed between participating centers and was obtained if required.
Variables
The following variables were prospectively collected in all participating centers: age, sex, smoking status and other vascular risk factors according to predefined criteria, 11 history of coronary artery disease, antithrombotic medication at stroke onset, initial stroke severity as assessed by the National Institutes of Health Stroke Scale (NIHSS) score, 12 stroke cause according to the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) criteria, 13 stroke onset-to-treatment time, and blood pressure and blood glucose level obtained at admission. Patency of extra-and intracranial arteries at baseline was assessed by the initial computed tomographic or magnetic resonance angiography in a subgroup of patients. All patients treated with IVT were admitted to intermediate or intensive care units for at least 24 hours. All patients underwent brain imaging with computed tomography or magnetic resonance imaging 24 to 48 hours after IVT and in any case of clinical deterioration.
Assessment of Outcomes
Clinical outcomes were assessed during outpatient visits using the modified Rankin Scale score at 3 months.
14 Main outcome measures in this study were (1) favorable outcome (defined as modified Rankin Scale score of 0 or 1), (2) death within 3 months, and (3) symptomatic intracerebral hemorrhage (sICH) according to the definition of the SITS-MOST (Safe Implementation of Thrombolysis in StrokeMonitoring Study). 15 In addition, we also used the Thrombolysis in Cerebral Infarction score on follow-up angiography 24 hours after IVT to evaluate arterial recanalization in a subgroup of patients with vessel occlusion of the M1 segment in middle cerebral artery. 16 The Thrombolysis in Cerebral Infarction scores of 2b (partial reperfusion of >50%) and 3 (complete reperfusion) were defined as successful recanalization.
17
Statistical Methods
We compared demographic and baseline characteristics between smokers and nonsmokers by using Fisher exact test for dichotomous variables and Mann-Whitney U test for continuous variables in univariate analyses. The independent effect of smoking status on outcome was assessed in a multivariable logistic regression model. Any variable with P<0.15 in the univariate analysis was entered into the regression model. Age and baseline NIHSS score were entered as mandatory into the model because they have been proven to be independent predictors of clinical outcome after stroke. 18 We additionally performed multivariable logistic regression analyses including clinically relevant outcome predictors (age, sex, NIHSS, and time to treatment for favorable outcome; age, sex, and NIHSS for mortality; age, sex, NIHSS, systolic blood pressure, baseline glucose, and antithrombotic treatment at baseline for sICH). 7, [18] [19] [20] [21] [22] The level of statistical significance was set to 0.05. Statistical analyses were conducted by using the statistical software R (version 3. 
Results
A total of 2237 patients were treated with IVT within study period. Data on smoking status were not available in 301 patients, and outcome data were missing in 71 patients. Thus, 1865 patients were eligible for this study. Of these, 369 (19.8%) were current smokers. The main baseline characteristics of the 2 groups are detailed in Table 1 . When compared with nonsmokers, smokers were more often male (72.1% versus 56.0%; P<0.001), were younger (mean 63.5 versus 71.3 years; P<0.001), and suffered less often from arterial hypertension (61.3% versus 70.1%; P=0.001) and atrial fibrillation (22.7% versus 35.6%; P<0.001). Stroke cause differed between the 2 groups (P<0.001) as cardioembolic stroke was more common among nonsmokers than smokers (48.2% versus 35%), whereas large artery atherosclerosis was more common among smokers than nonsmokers (17.4% versus 11.6%). However, stroke severity indicated by baseline NIHSS score was comparable between the groups (mean, 11.0 versus 11.4; P=0.417). Nonsmoking patients were more often treated with antithrombotic drugs at baseline (46.7% versus 39%; P=0.008). Vessel occlusion was documented in 959 (51.4%) patients. Imaging at baseline showed arterial occlusion in 174 of 369 (47.1%) smokers and in 785 of 1496 (52.4%) nonsmokers. Extracranial occlusion of internal carotid artery occurred more frequently in smokers (21.8% versus 12.6%), whereas intracranial occlusions in anterior cerebral circulation such as carotid T (4.6% versus 4.3%) or M1 segment in middle cerebral artery (31% versus 35.3%) were comparable with nonsmokers.
Clinical outcomes are summarized in Table 2 . At 3 months, smokers had higher rates of favorable outcome (45.8% versus 39.5%; P=0.029) and lower mortality rates (9.8% versus 15.8%; P=0.003) than nonsmokers, whereas the rates of sICH did not significantly differ between the groups (3.0% versus 3.8%; P=0.536).
For multivariable regression analyses, the following covariates were entered into the model: age, sex, baseline NIHSS, atrial fibrillation, arterial hypertension, baseline use of antithrombotics, baseline blood glucose, and stroke cause according to TOAST classification ( 
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In patients with occlusion of M1 segment in middle cerebral artery, radiological recanalization was significantly more often documented in smokers than in nonsmokers (72.7% versus 56%; P=0.045). After multivariable adjustment, smoking was still associated with recanalization (OR, 2.68; 95% CI, 1.11-6.43; P=0.028), together with NIHSS (P=0.045) and cardioembolic stroke cause (P=0.002).
In addition, we performed a sensitivity analysis by running the same multivariable regression model without adjustment for the NIHSS score. However, the overall conclusion did not change as smoking was still associated with recanalization (OR, 2.24; 95% CI, Results of additional outcome analyses including clinically relevant predictors are summarized in Table III in the onlineonly Data Supplement. Age and NIHSS again independently predicted all clinical outcomes (favorable outcome, mortality, and sICH), whereas no association was observed between smoking and clinical outcome.
Discussion
This large multicenter cohort study on 1865 patients with acute ischemic stroke suggests that good outcome in smokers after IVT as shown in unadjusted analyses is probably related to differences in baseline characteristics as multivariable analyses revealed no significant association between smoking status and clinical end points (favorable outcome, mortality, and sICH).
Considering differences in baseline characteristics is crucial for discussion of smoking paradox in stroke patients. In line with the literature, smokers were significantly younger, more likely to be male, and suffered less often from atrial fibrillation than nonsmokers. 23, 24 Accordingly, stroke caused by cardioembolism occurred significantly more often among nonsmokers than in smokers. It has been shown, that older age is one of the most important and independent predictors for death and unfavorable outcome in stroke. 25, 26 Furthermore, female sex has been reported to correlate with worse outcome after stroke. [26] [27] [28] Of note, the proportion of male sex was higher in smokers than in counterpart. Cardioembolic stroke caused by atrial fibrillation is known to be associated with large territorial infarcts, longer and tight thrombus formation, higher risk of hemorrhagic transformation, and unfavorable clinical outcomes. [29] [30] [31] [32] [33] In line with this, noncardioembolic strokes may be independently related to good outcome in smoking patients treated with IVT. 34 Thus, these imbalances at stroke onset may explain the impression of favorable outcome in smokers (smoking paradox). Multivariable analyses in our study revealed that clinical recovery and mortality was not related to smoking status, but age, stroke severity (measured by using NIHSS), and blood glucose. These findings are in line with literature. 20, 35, 36 Furthermore, the risk of sICH was comparable in smokers and in nonsmokers (both in univariate and multivariable analyses), whereas few studies suggested lower risk of sICH in smokers treated with tPA. 7, 34 Our findings are in line with other IVT studies that failed to demonstrate an independent association of smoking status with 3-month outcome.
24,37-39 Only 1 study showed an independent relation between current smoking and favorable short-term outcome, but outcomes were assessed at 1 week after thrombolysis or earlier. 8 In addition, the sample size of smokers was rather low (n=94). 8 A subgroup analysis in patients with M1 segment in middle cerebral artery occlusion showed higher recanalization rates in smokers. The association with smoking remained still significant after multivariable adjustment. Our findings fit to previously published studies showing that smoking was associated with recanalization and reperfusion in smokers treated with tPA for ischemic stroke. 34, 40 Two reasons might explain our observation. First, arterial occlusions in smokers may be rather thrombogenic because smoking is associated with a hypercoagulable state mediated by increased hematocrit and fibrin-rich clots, higher fibrinogen levels, and impaired endogenous fibrinolytic capacity. 41, 42 This may explain the better response to thrombolytic treatment in smokers with higher rates of recanalization. In line with this, higher rates of arterial recanalization have been reported in smoking patients with acute myocardial infarction undergoing systemic thrombolysis. 5, [43] [44] [45] On the other hand, arterial occlusion in nonsmokers may be more frequently caused by rupture or ulceration of atheromatous plaque with no or little response to thrombolytic treatment. Second, smoking has also been associated with increased plasma levels of carbon monoxide and episodic hypoxia 46 which could lead to ischemic preconditioning and may trigger adaptive cellular responses to ischemia. 47, 48 However, the results on arterial recanalization should be interpreted with caution as data originate from subgroup analyses with a low number of patients in our study (n=331) and former studies (n=79). 37 In accordance with our study, NIHSS on admission but not smoking status was an independent predictor of functional recovery. 37 The hazardous effect of cigarette smoking is reflected by the occurrence of stroke many years earlier than in nonsmokers.
The main strength of our study is the large cohort size and multicenter design, which allows adjustment for potential confounders. This is to our best knowledge the largest outcome study assessing relationship between IVT and smoking status in 1865 stroke patients when compared with former studies in white patients (range, 148-399; mean, 299). 8, 24, 38 Thus, the markedly larger sample size of our study will result in better statistical power than in previous studies. Furthermore, data quality was high as both clinical and radiological data were systematically and prospectively collected at baseline and during 3-month follow-up.
This study has also some limitations. First, this was an observational, nonrandomized study with a higher risk of bias which may not be completely removed through the multivariable model. We did not systematically record the quantity of smoking exposure, leading to high heterogeneity in our smoking cohort and prohibiting a differentiation of heavy versus mild smokers and to assess a dose-response relationship between smoking and outcome. Lacking data on earlier smoking status, we were not able to compare outcomes in current smokers versus former smokers. Despite covariate adjustments, there may be hidden confounders we did not consider in our study such as differences in rehabilitation, socioeconomic status, caregiver support, medical complications, and recurrent strokes within 3 months after event. Furthermore, data on occlusion and recanalization were only available in a subgroup of patients accounting for 14% of the entire cohort. Thus, data on recanalization need to be interpreted cautiously given the small sample size and the large number of covariates adjusted for. Finally, we did not measure changes in smoking habits (eg, cessation) after stroke, which may also have influenced the 3-month outcomes.
Conclusions
Our data indicate that smoking has no beneficial effect on stroke outcome after IVT and contradict the hypothesis of a smoking paradox in stroke. The apparently good outcome in smokers was largely related to younger age and other differences in baseline characteristics. Although the odds for arterial recanalization after IVT might be higher in smokers because of different pathophysiologic mechanisms, the earlier occurrence of stroke in the lifetime of smokers offsets a potential benefit in recanalization.
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